Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00189449
Status:
COMPLETED
Last Update Posted:
2008-05-01
First Post:
2005-09-12
Brief Title:
Effects of Long-Term Treatment With Nasally Inhaled Triamcinolone Acetonide in Children With Allergic Rhinitis
Sponsor:
West Penn Allegheny Health System
Organization:
West Penn Allegheny Health System
Study Overview
Official Title:
Effects of Long-Term Treatment With Nasally Inhaled Triamcinolone Acetonide in Children With Allergic Rhinitis
Status:
COMPLETED
Status Verified Date:
2008-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Seasonalperennial allergic rhinitis SARPAR is a common childhood illness One of the leading therapies for the treatment of SARPAR is intranasally inhaled corticosteroids ICS One of the major long-term safety concerns is whether ICS interferes with normal growth in allergic rhinitis children Recent evidence suggests that nasal ICS may cause decreased growth However the effect of nasal ICS on long-term growth and the attainment of final adult height is unknown Another potential systemic adverse effect of ICS use is suppression of the hypothalamic-pituitary-adrenal axis function The primary hypothesis of this study is that triamcinolone acetonide aqueous nasal spray TAA will have no effect on measured adult height in relation to target adult height in children with allergic rhinitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| RC - 3421 | None | None | None |